scholarly journals The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia

2017 ◽  
Vol 1 (13) ◽  
pp. 802-811 ◽  
Author(s):  
Lucy C. Fox ◽  
Katherine D. Cummins ◽  
Ben Costello ◽  
David Yeung ◽  
Rebecca Cleary ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
Pleural Effusion ◽  
Chronic Myeloid Leukemia ◽  
Natural History ◽  
Myeloid Leukemia ◽  
Key Points ◽  
History Of

Key PointsPrescribing appropriately for age and cardiovascular risk is likely to result in minimal permanent toxicity-related dasatinib cessation. CML patients on dasatinib with pleural effusion are more likely to have achieved MR4.5 after 6-month therapy than those without effusion.

scholarly journals The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia

2019 ◽  
Vol 3 (7) ◽  
pp. 1084-1091 ◽  
Author(s):  
Adrian G. Minson ◽  
Katherine Cummins ◽  
Lucy Fox ◽  
Ben Costello ◽  
David Yeung ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Natural History ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Chronic Phase ◽  
Molecular Response ◽  
Increased Risk ◽  
History Of ◽  
Dose Modifications

Abstract Although second-generation tyrosine kinase inhibitors (TKIs) show superiority in achieving deep molecular responses in chronic myeloid leukemia in chronic phase (CML-CP) compared with imatinib, the differing adverse effect (AE) profiles need consideration when deciding the best drug for individual patients. Long-term data from randomized trials of nilotinib demonstrate an increased risk of vascular AEs (VAEs) compared with other TKIs, although the natural history of these events in response to dose modifications or cessation has not been fully characterized. We retrospectively reviewed the incidence of nilotinib-associated AEs in 220 patients with CML-CP at 17 Australian institutions. Overall, AEs of any grade were reported in 95 patients (43%) and prompted nilotinib cessation in 46 (21%). VAEs occurred in 26 patients (12%), with an incidence of 4.1 events per 100 patient-years. Multivariate analysis identified age (P = .022) and dyslipidemia (P = .007) as independent variables for their development. There was 1 fatal first VAE, whereas the remaining patients either continued nilotinib (14 patients) or stopped it immediately (11 patients). Recurrent VAEs were associated with ongoing therapy in 7 of 14 who continued (with 2 fatal VAEs) vs 1 of 11 who discontinued (P = .04). Nineteen of the 23 evaluable patients surviving a VAE ultimately stopped nilotinib, of whom 14 received an alternative TKI. Dose reduction or cessation because of VAEs did not adversely affect maintenance of major molecular response. These findings demonstrate that in contrast to other AEs, VAEs are ideally managed with nilotinib cessation because of the increased risk of additional events with its ongoing use.

Natural History of Southeast Asian Chronic Myeloid Leukemia Patients with Different BCR-ABL Gene Variants

2006 ◽  
Vol 116 (2) ◽  
pp. 114-119 ◽  
Author(s):  
C.U. Auewarakul ◽  
S. Huang ◽  
M. Yimyam ◽  
S. Boonmoh
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Natural History ◽  
Myeloid Leukemia ◽  
Southeast Asian ◽  
Gene Variants ◽  
History Of

scholarly journals Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia

Cancer ◽  
2021 ◽  
Author(s):  
Guillermo Montalban‐Bravo ◽  
Rashmi Kanagal‐Shamanna ◽  
Koji Sasaki ◽  
Lucia Masarova ◽  
Kiran Naqvi ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Natural History ◽  
Myeloid Leukemia ◽  
History Of ◽  
Atypical Chronic Myeloid Leukemia

scholarly journals HHV8-Negative Effusion-Based Large B Cell Lymphoma Arising in Chronic Myeloid Leukemia Patients under Dasatinib Treatment: A Report of Two Cases

Biology ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 152
Author(s):  
Stefano Fiori ◽  
Elisabetta Todisco ◽  
Safaa Ramadan ◽  
Federica Gigli ◽  
Patrizia Falco ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Chronic Myeloid Leukemia ◽  
B Cell ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Present Report ◽  
Treatment Decision ◽  
B Cell Lymphoma ◽  
Patient Case ◽  
Large B Cell

Tyrosine kinase inhibitors (TKIs) are the treatment of choice for BCR-ABL1-positive chronic myeloid leukemia (CML). Although TKIs have substantially improved prognosis of CML patients, their use is not free of adverse effects. Dasatinib is a second generation TKI frequently associated with pleural effusion in up to 33% of patients. This results in symptoms as dyspnea, cough and chest pain that may require therapy discontinuation. In the present report, we describe two exceptional cases of HHV8-negative large B-cell effusion-based lymphoma (EBL) confined to the pleura, incidentally, diagnosed in patients presenting with dasatinib-related pleural effusion. One patient (case 1) is alive and is in remission at 17 months from large B-cell EBL diagnosis while unfortunately the other patient (case 2) died of progressive disease and COVID-19 pneumonia 16 months from large B-cell EBL diagnosis. These cases raise concern about a possible association between large B-cell EBL and dasatinib, and the different clinical outcome of the two cases poses a challenge in treatment decision. For this reason, we strongly recommend cytological investigation in patients with persistent/relapsing pleural effusion under dasatinib, primarily to validate its possible association with lymphoma development and to improve the knowledge about this entity.

scholarly journals Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship

Cancer ◽  
2016 ◽  
Vol 123 (4) ◽  
pp. 609-616 ◽  
Author(s):  
Paul B. Koller ◽  
Hagop M. Kantarjian ◽  
Graciela M. Nogueras‐Gonzalez ◽  
Elias Jabbour ◽  
Srdan Verstovsek ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
History Of

Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia

Blood ◽  
2014 ◽  
Vol 123 (25) ◽  
pp. 3951-3962 ◽  
Author(s):  
Harald Herrmann ◽  
Irina Sadovnik ◽  
Sabine Cerny-Reiterer ◽  
Thomas Rülicke ◽  
Gabriele Stefanzl ◽  
...  
Keyword(s):  
Stem Cells ◽  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Specific Marker ◽  
Leukemic Stem Cells ◽  
Dipeptidylpeptidase Iv ◽  
Key Points

Key Points DPPIV (CD26) is a new specific marker of CML LSC that aids CML diagnostics and the measurement, characterization, and purification of LSC. DPPIV on CML LSC degrades SDF-1 and thereby promotes the niche-escape of LSC, which may contribute to extramedullary myeloproliferation in CML.

scholarly journals Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia

Open Medicine ◽  
2018 ◽  
Vol 14 (1) ◽  
pp. 22-24 ◽  
Author(s):  
Umit Y. Malkan ◽  
Ibrahim C. Haznedaroglu
Keyword(s):  
Pleural Effusion ◽  
Chronic Myeloid Leukemia ◽  
Serum Creatinine ◽  
Imatinib Mesylate ◽  
Myeloid Leukemia ◽  
Laboratory Tests ◽  
Fluid Retention ◽  
X Ray ◽  
Cytogenetic Remission

AbstractWe aim to report a CML case that had fluid retention and serum creatinine increase under long-term imatinib mesylate (IM) treatment. A 68-year-old woman was diagnosed with chronic myeloid leukemia, and IM was started in 2002 with a dose of 400 mg/day. She had achieved complete hematological, molecular and cytogenetic remission under IM treatment. In September 2015, her creatinine level was 1.7 mg/dl. In May 2016, she was admitted to our hospital with dyspnea. Hypervolemia secondary to fluid retention was detected in our patient. Her laboratory tests results showed hemoglobin 9.7 gr/dl, white blood cell 7.6x103/μl, platelet 157x103/μl, creatinine 3.2 mg/dl, blood urea nitrogen (BUN) 88 mg/dl. In her X-ray chest film, bilateral pleural effusion was detected. The effusion was detected as transuda. The other reasons of pleural effusion were excluded and the development of pleural effusion was considered secondary to IM. IM was also considered responsible for the acute rise of serum creatinine levels of our patient. Therefore for these two reasons IM was stopped. After the discontinuation of IM, her creatinine levels decreased to 1.6 mg/dl and her pleural effusions disappeared. IM treatment was considered as the reason of serum creatinine elevation since serum creatinine levels decreased after the discontinuation of IM. All of the side-effects disappeared after discontinuation of IM.

Sign in / Sign up

Export Citation Format

Share Document